Core Viewpoint - The inclusion of the HPV vaccine in the national immunization program is a significant step towards improving public health and addressing the issue of insufficient effective market demand in China [1][2][5]. Group 1: HPV Vaccine Inclusion - The HPV vaccine will be included in the national immunization program starting November 10, 2025, providing free vaccinations for girls aged 13 and above [1]. - This marks the first new vaccine added to the national immunization program since 2007 and expands the target demographic from children under 6 to adolescents [1][2]. - The vaccine is a bivalent type targeting high-risk HPV types 16 and 18, with a planned procurement of 15.4465 million doses at a unit price of approximately 27.5 yuan [2]. Group 2: Public Health and Economic Impact - The HPV vaccination initiative is expected to significantly reduce healthcare costs for individuals and society, improving the asset-liability structure for families and the nation [3]. - By providing preventive healthcare services, the program aims to lower health risks for individuals and the broader community, addressing the issue of poverty caused by illness [3]. - The initiative is seen as a proactive fiscal policy that invests in public health, which is crucial for enhancing overall economic productivity and addressing the current lack of effective demand in the market [2][3][4]. Group 3: Addressing Market Demand Issues - The current economic challenge in China is characterized by insufficient effective demand, primarily due to a lack of security in social welfare systems, leading to increased personal savings [4]. - The HPV vaccination program is viewed as a practical measure to fill gaps in social security and healthcare, ultimately helping to convert excess savings into effective purchasing power [4][5]. - The government is expected to focus fiscal resources on public welfare, enhancing health and safety for citizens, which will help alleviate issues related to insufficient domestic demand [5].